ASCO spotlights daraxonrasib in GI

Ahead of the 2026 ASCO Annual Meeting, gastrointestinal cancer specialists are zeroing in on daraxonrasib as one of the meeting’s most closely watched datasets. OncLive reported on May 14 that experts it interviewed across GI oncology repeatedly pointed to the drug’s phase 3 RASolute 302 study in previously treated metastatic pancreatic ductal adenocarcinoma as the presentation drawing the most attention. Daraxonrasib is an oral, multi-selective RAS inhibitor being developed by Revolution Medicines for tumors driven by RAS signaling. The company said on April 21 that detailed results from RASolute 302 will be presented in ASCO’s plenary session in Chicago, where the meeting runs from May 29 to June 2. (onclive.com) Here’s the thread on why that matters in GI oncology right now: 1/ The focal point is pancreatic cancer, not GI oncology in the abstract. OncLive’s May 14 ASCO preview said the “biggest story” in GI at the meeting is the phase 3 RASolute 302 trial in pancreatic ductal adenocarcinoma, with UCLA’s Zev Wainberg saying, “Everyone’s excited about the data with daraxonrasib in pancreatic cancer.” (ir.revmed.com) 2/ The reason is the topline efficacy claim. Revolution Medicines said daraxonrasib met all primary and key secondary endpoints in RASolute 302, showing statistically significant improvement in progression-free survival and overall survival versus standard intravenous cytotoxic chemotherapy. 3/ The headline number already circulating is overall survival. (onclive.com) The ASCO Post, citing the company’s mid-April release, reported median overall survival of 13.2 months for daraxonrasib versus 6.7 months for investigator’s choice chemotherapy in previously treated patients, with a hazard ratio of 0.40. 4/ That is why the plenary slot matters. (ir.revmed.com) ASCO scheduled the primary and final analysis of RASolute 302 as abstract LBA5 in the plenary session on May 31, with Dana-Farber’s Brian Wolpin listed as presenting author. 5/ The drug is drawing attention because it aims at a broad biologic target in pancreatic cancer. (ascopost.com) MD Anderson and Dana-Farber both said more than 90% of pancreatic cancers harbor RAS or KRAS-driven alterations, making a multi-selective RAS inhibitor potentially relevant to a much larger share of patients than mutation-specific drugs used in other tumor types. (ir.revmed.com) 6/ The earlier-stage data helped set up the phase 3 moment. MD Anderson said a phase 1/2 study published May 6 in the New England Journal of Medicine showed a 29% response rate and median overall survival of 15.6 months among 38 patients treated at the 300 mg dose level. The same report said 30% had grade 3 or higher adverse events, with rash, diarrhea, stomatitis or mucositis, and fatigue among the most common side effects. (mdanderson.org) 7/ Investigators are also framing daraxonrasib as part of a broader GI targeted-therapy wave, not a one-off story. OncLive said Wainberg and other specialists are watching additional KRAS-directed studies in pancreatic and colorectal cancer, while also flagging newer drugs, antibody-drug conjugates and bispecifics in gastric cancer. (mdanderson.org) 8/ The near-term question is whether the full ASCO data hold up under closer scrutiny. OncLive said experts are waiting to see whether the complete RASolute 302 presentation confirms the topline survival result strongly enough to support a new standard approach in previously treated metastatic pancreatic cancer; that characterization was attributed to the physicians it interviewed. (onclive.com) 9/ The next concrete checkpoint is May 31. That is when Wolpin is due to present the full phase 3 dataset in Chicago, alongside additional efficacy and safety analyses that Revolution Medicines said will accompany the primary and final trial readout. (ir.revmed.com) (onclive.com)